News
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...
Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback